It was found that, in AITL, patients expressing CD7 had a better prognosis, whereas patients expressing CD38 and Ki-67 had a poorer prognosis (Figure 7), It may suggest that tumor cells with more active proliferative capacity are more aggressive. This evidence concerns the gene CD38 and angioimmunoblastic T-cell lymphoma.